"This is for a niche
population — treatment-resistant depression — so overall impact to the category
as a whole and majority of drug spend will be quite minimal. However, compared
to using generic ketamine injection, it will increase costs."
— April Kunze, Pharm.D., senior director, clinical formulary
development and trend management strategy at Prime Therapeutics LLC., talked
with AIS's Health Plan Weekly
about Spravato's market entrance, and its potential impact on treating
depression.
No comments:
Post a Comment